跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 90 条关于
“BRAFV600”
全部
90
临床试验
74
药物
0
机构
0
资讯
16
4年前
FORE Biotherapeutics Highlights Recent Pipeline Achievements and Strategic Objectives for 2025
去年
FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission
去年
ctDNA Monitoring Shows Promise for Predicting Melanoma Recurrence After Surgery
3年前
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment for BRAFV600E-Mutant Metastatic Colorectal Cancer
3年前
Real-world First-line Treatment Patterns and Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer in Europe
2年前
European Commission Approves Encorafenib and Binimetinib Combination for BRAF V600E-Mutant NSCLC
10个月前
Ono Pharmaceutical Secures Approvals for BRAFTOVI Combination Therapy in BRAF-Mutant Colorectal Cancer
去年
CAIRO5 Trial: FOLFOX/FOLFIRI Plus Bevacizumab Shows Efficacy in Unresectable Colorectal Liver Metastases
去年
Comprehensive Genomic Analysis Reveals Key Metastatic Pathways and Drug Targets in Thyroid Cancer
2个月前
Landmark NHS Approval of Dabrafenib and Brentuximab-Vedotin Combination Offers New Hope for Patients with Rare Blood Cancers
第 1 页,共 2 页
上一页
下一页